•There is no enough evidence to indicate that ACEIs and ARBs result in ACE2 upregulation.•The level of ACE2 expression is not completely related with the risk of COVID-19 infection.•There is currently no evidence that ACEI/ARB increase risk for COVID-19 infection from clinical trials.•It is not recommended that COVID-19 patients with hypertension or normal hypertensive patients at risk for exposure to stop using ACEI/ARB or change to other antihypertensive drugs.

中文翻译：

---

致编辑的信：抗 RAS 药物和 SARS-CoV-2 感染。


•没有足够的证据表明ACEI和ARB会导致ACE2上调。•ACE2表达水平与COVID-19感染风险并不完全相关。•目前没有证据表明ACEI/ARB会增加COVID-19感染风险临床试验中-19感染。•不建议患有高血压的COVID-19患者或有暴露风险的正常高血压患者停止使用ACEI/ARB或改用其他降压药。